Several corporates backed a $68m series D round for microbiome drug developer Vedanta Biosciences while grooming brand owner Pangaea raised the same amount from investors including Unilever.
Funding
US-based microbiome therapy developer Vedanta Biosciences completed a $68m series D round yesterday that included a $25m investment from pharmaceutical firm Pfizer and additional cash from synthetic rubber producer JSR Corporation, healthcare services provider SymBiosis and Fosun Health Capital, a vehicle for conglomerate Fosun. Affiliates of Magnetar Capital led the round, which also featured Verition Fund Management, PureTech Health, Rock Springs Capital, Skyviews Life Science, Shumway Capital and Seventure Partners’ Health for Life Capital subsidiary. Vedanta had previously raised over $112m as of a $62m series C round in 2019 featuring JSR and pharmaceutical firm Bristol-Myers Squibb.
US-headquartered men’s grooming product provider Pangaea Holdings raised $68m yesterday from investors including Unilever Ventures, the corporate venturing arm of consumer product manufacturer Unilever, and internet technology provider Google’s Gradient Ventures fund. Asset management firm Eurazeo invested $53m to lead the round, which also featured GPO Fund and Base10 Partners.…
